Purpose: There is an urgent need for the development of novel, effective, and less toxic drugs to treat leukemia. Antimicrobial peptides (AMPs) have received much more attention as alternative chemotherapeutic agents. This study aimed to examined the cytotoxicity of a novel AMP myristoly-CM4 against chronic myeloid leukemia cells (K562/MDR) and acute lymphocytic leukemia cells (Jurkat), and further investigated its selectivity to clarify the cytotoxic mechanism. Materials and methods: In this study, the cytotoxicity and selectivity of myristoly-CM4 against K562/MDR and Jurkat cells were assessed in vitro, and the anticancer mechanism responsible for its cytotoxicity and selectivity was further investigated. Results: Myristoly-CM4 was cytotoxic to these leukemia cell lines (IC50 2-4 μM) and was less cytotoxic to normal cells (HEK-293, L02 cells, peripheral blood mononuclear cells, and erythrocytes). Myristoyl-CM4 had stronger affinity to K562/MDR and Jurkat cells than to normal cells, while the contents of phosphatidylserine and sialic acids on the cell surfaces of K562/MDR and Jurkat cells were significantly higher than that of HEK293 cells. The myristoyl group effectively mediated the internalization of myristoyl-CM4 to leukemia cells. After internalization, myristoyl-CM4 could target mitochondria and affected mitochondrial function, including disruption of Δψm, increasing the accumulation of ROS, increasing the Bax/Bcl-2 ratio, activating caspase 9 and 3, and PARP to induce mitochondria-dependent apoptosis in both K562/MDR and Jurkat cells. Myristoyl-CM4 also induced K562/MDR cell necrosis by directive membrane disruption, and significantly decreased the level of P-glycoprotein in K562/MDR cells. Conclusion: These results suggested that myristoyl-CM4 showed selective cytotoxicity to leukemia K562/MDR and Jurkat cells by apoptosis and/or necrosis pathway. Myristoyl-CM4, thus, appears to be a promising candidate for leukemia treatment, including multidrugresistant leukemia.
Introduction
Despite major advances over the past few years, cancer remains a serious threat to human survival. Leukemia is the most common form of cancer worldwide, with an estimated 437,033 new cases and 309,000 deaths predicted in 2018. 1 Leukemia results from the clonal proliferation of bone marrow cells with impaired differentiation, regulation, and cell death. There have been breakthroughs in bone marrow transplantation for the treatment of childhood leukemias in recent decades, but chemotherapy remains the main treatment option for adults, with less therapeutic ditional chemotherapeutic drugs used in the clinic, such as doxorubicin and arsenic trioxide, show insufficient selectivity, resulting in deleterious side-effects. 5, 6 The development of novel safe and effective drugs, thus, remains an urgent priority for leukemia treatments. Cationic antimicrobial peptides (AMPs) have shown antibacterial, antifungal, wound healing, antioxidant, and anticancer properties. About 200 natural and synthetic animal AMPs have demonstrated the ability to kill cancer cells, especially from solid tumors in vivo or in vitro. 7 AMPs usually kill cancer cells by interacting with specific targets exposed in cancer cell plasma membranes, thus improving their selectivity for cancer cells compared with traditional chemotherapeutic drugs. 8 However,
although several AMPs have shown anticancer activity in leukemia cells, most were not effective enough. [9] [10] [11] [12] The AMP CM4 consists of 35 amino acids, and was initially isolated from the hemolymph of the Chinese silkworm Bombyx mori. CM4 was effective against bacteria and fungi, via affecting membrane interactions. 13, 14 It also showed anti-inflammatory effects mediated by neutralizing the endotoxin lipopolysaccharide. 15 In addition to its antimicrobial activity, we previously reported that CM4 had selective anticancer activity in leukemia cells (K562, THP-1, and U937 cells), while exhibiting no cytotoxicity towards noncancer cells, even at 120 μM. 16 Targeting leukemia cells and disrupting their plasma membrane are major anticancer mechanisms. However, similar to most AMPs, the anticancer activity in leukemia cells was low (IC 50 about 20-40 μM), thus hampering its use in leukemia therapy. Covalent modification of proteins by fatty acids such as myristate or palmitate is a widely-recognized form of protein modification and plays an essential role in directing the cellular localization of proteins by facilitating protein-membrane interactions. 17 Several groups have reported that the conjugation of fatty acids to AMPs improved their hydrophobicity, resulting in the enhancement, retention, or loss of antimicrobial activity. [18] [19] [20] We previously showed that conjugation of a myristoyl group to the N-terminus of CM4 significantly enhanced its antitumor activity in breast cancer both in vitro and in vivo, resulting in the induction of mitochondria-dependent apoptosis in breast cancer cells. 21 However, its anticancer activity against non-solid tumors such as leukemias remains unknown. In the current study, we assessed the cytotoxicity of myristoyl-CM4 against human chronic myeloid leukemia K562/MDR and T-cell acute leukemia Jurkat cells in vitro, and further investigated its selectivity to clarify the cytotoxic mechanism responsible for its action.
Materials and methods
Peptide synthesis, labeling, and reagents CM4 (GRWKIFKKIEKVGQNIRDGIVKAGPAVAVVGQ AATI-NH 2 ), myristoyl-CM4, fluorescein isothiocyanate (FITC)-CM4, and FITC-lmyristoyl-CM4 were synthesized using solid-phase 9-fluorenylmethoxycarbonyl (Fmoc) methods by Biomatik Corporation (Ontario, Canada). The synthesized peptides used were all >95% homogeneous, as indicated by C18 reverse-phase high-performance liquid chromatography (HPLC) and electrospray ionization mass spectroscopy analysis. RPMI-1640 and DMEM were purchased from Thermo Fisher Scientific (Waltham, MA, USA), FBS from Capricorn scientific (Hessen, Germany). Melittin was purchased from Synpeptide, Inc (Nanjing, China). MTT, rhodamine 123, and Triton-X-100 were purchased from Sigma-Aldrich (St. Louis, MO, USA). Hoechst 33342/PI staining kit, ROS assay kit, and DCFH-DA were purchased from Beyotime Insititue of Biotechnology (Shanghai, China). JC-1 Detection kit, Annexin V/PI assay kit, and LDH assay kit were purchased from KeyGEN BioTECH, Inc. (Nanjing, China). FITC-SNA were purchased from Vector Laboratories (Burlingame, CA, USA). Bax(# 5023), Bcl-2(# 2870), cytochrome c(# 11940), caspase 9(# 9508), caspase 3(# 9662), PARP(# 9542), GAPDH(# 2118), β-actin(# 4967) and P-gp(# 13342) were purchased from Cell Signaling Technology (Boston, MA, USA). All the antibodies were used at a dilution multiple of 1:1,000. All other reagents were analytical grade reagents, and produced in China. All the reagents were used by the rules of standard biosecurity and safety procedures of Nanjing Normal University. 
Cell culture

Hemolytic activity assay
Erythrocytes were isolated from mouse blood cells by centrifugation at 1,000×g for 10 minutes, followed by washing three times with PBS. Hemolytic activity was evaluated as the method described previously. 21 
Annexin V/PI staining
Apoptosis was evaluated using two-color flow cytometric analysis with an Annexin V/PI assay kit. Briefly, 2.5×10 on ice in the dark. The stained cells were analyzed by flow cytometry, and the percentage of apoptotic cells was calculated using Cell Quest software.
Measurement of the contents of phosphatidylserine and sialic acid
The contents of phosphatidylserine (PS) and sialic acid on the surface of K562/MDR, Jurkat, and HEK293 cells were determined using flow cytometry. Brifely, cells at concentrations above 1×10 6 cells/mL were stained with FITCAnnexin V for 15 minutes, or 10 μg/mL of FITC-SNA for 45 minutes at 4°C in the dark. The cells were washed with PBS and analyzed using a flow cytometer. The mean fluorescence of 10,000 cells was analyzed for each sample. Data were reported as the mean±SEM of three independent experiments.
Hoechst 33342/PI staining 
Lactate dehydrogenase (LDH) release
The LDH assay was performed according to the manufacturer's protocol. Briefly, K562/MDR and Jurkat cells (1×10 5 /mL) were cultured in RPMI 1640 medium at 37°C for 4 hours and then incubated with different concentrations of myristoyl-CM4 or CM4 (3, 9, 30 μM) for different times. PBS and 2% Triton X-100 were used as controls. After centrifugation of the microtiter plates, 100 μL of cell-free culture supernatant was transferred into new microtiter plates and a tetrazolium salt reaction mixture was added to each plate, according to the manufacturer's protocol. The absorbance of the colored formazan was determined using a microplate reader at 490 nm. LDH leakage (%) was calculated using the following equation: [(A−C)/(P−C)]×100, where A is the mean absorbance in the test wells, C is the PBS control, and P is the Triton X-100 control. Data were reported as mean±SEM of four independent experiments.
JC-1 assay
Change in mitochondrial membrane potential (Δψm) was detected using a mitochondria staining kit with JC-1 as a cationic fluorescent dye. Briefly, K562/MDR and Jurkat cells (2×10 6 /mL) were cultured in the absence or presence of myristoyl-CM4 (3 μM for K562/MDR and 6 μM for Jurkat) for 12 hours. The cells were then collected, washed in ice-cold PBS, and incubated with 10 μg/mL for 30 minutes at room temperature. The cells were washed with JC-1 washing buffer and analyzed by flow cytometry. Flow cytometry was performed at 490 nm excitation and 530 nm emission wavelengths for JC-1 monomers and for 525 nm excitation and 590 nm emission wavelengths for JCaggregates. 
Detection of ROS accumulation
Western blotting analysis
K562/MDR and Jurkat cells were incubated with myristoyl-CM4 for 16 hours and the expression of P-glycoprotein (P-gp) was then detected. Briefly, the cells were harvested in cell lysis buffer containing protease inhibitors, followed by centrifugation at 15,000×g for 10 minutes. The supernatant was collected, separated by 8% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and transferred onto a polyvinylidene difluoride (PVDF) membrane. To detect the apoptosis pathway induced by the peptides, leukemia cells (5×10 6 cells) were cultured with different concentrations of myristoyl-CM4 for 16 hours, harvested in cell lysis buffer, and centrifuged at 15,000×g for 10 minutes. Supernatants were collected, separated by 12% SDS-PAGE, and transferred onto a PVDF membrane. The membranes were blocked with 5% bovine serum albumin and probed with polyclonal antibodies against P-gp, Bcl-2, Bax, caspase-9, caspase-3, PARP, β-actin, and GAPDH. Protein bands were visualized using the Odyssey infrared imaging system.
Statistical analysis
Values were expressed as mean±SEM from three-to-six independent experiments. Differences were analyzed by Two-tailed Student's t-test and one-way ANOVA with Figure 1C ). The reduction in cell viability was more effective in K562/MDR compared with Jurkat cells, with IC 50 values of 2 μM and 3 μM, respectively. There was no difference in the toxicity of myristoyl-CM4 to K562 cells and K562/MDR cells, so K562/MDR cells were selected for further study ( Figure 1D ). The results of the Trypan Blue exclusion assay further supported the above results ( Figure  1E ), and very few viable cells were observed at a concentration of 8 μM.
Myristoyl-CM4 was less cytotoxic normal cells compared with leukemia cells
The cytotoxicities of CM4 and myristoyl-CM4 against normal mammalian cells (HEK293 and L02 cells) were detected by MTT assay (Figure 2A ). More than 95% of cells remained viable after treatment with 10 μM myristoyl-CM4, and more than 60% after treatment with 40 μM, indicating that myristoyl-CM4 exhibited low cytotoxicity against HEK-293 and L02 cells. Hemolytic assay using mouse erythrocytes showed no hemolysis following treatment with 3 μM myristoyl-CM4 ( Figure 2B ), and only 2% hemolysis at a concentration of 10 μM; however, hemolysis increased to 20% at a concentration of 30 μM. The cytotoxicity of myristoyl-CM4 against mouse PBMCs was detected by Trypan Blue exclusion assay. The number of PBMCs was not reduced, and no dead PBMCs were observed after incubation for 24 hours with 2 μM myristoyl-CM4 ( Figure 2C ). In contrast, the AMP melittin isolated from honey bee (A. mellifera) venom resulted in 100% cytotoxicity of PBMCs at 2 μM. Treatment with 10 μM myristoyl-CM4 still resulted in more than 80% viable PBMCs, suggesting that myristoyl-CM4 showed selective cytotoxicity against leukemic K562/MDR and Jurkat cells.
Myristoyl-CM4 had higher affinity to leukemia cells compared with normal cells
The effect of the myristoyl group on the membrane affinity of myristoyl-CM4 was analyzed by FITC labeled peptide and fluorescence-activated flow cytometry. The fluorescence intensity was significantly higher than that of CM4 ( Figure 3A ). Compared with FITC-CM4, the FITC fluorescence intensities of myristoyl-CM4 were increased 14-fold and 19-fold in K562/MDR and Jurkat cells, respectively ( Figure 3B ). The fluorescence intensities of FITC-myristoyl-CM4 were very weak in normal HEK293 cells and mouse erythrocytes. The FITC fluorescence intensities in K562/MDR and Jurkat cells were 27.6-fold and 82.1-fold higher than in normal HEK293 cells, and 23.4-fold and 69.7-fold higher than in mouse erythrocytes. The binding activity was further analyzed by CLSM ( Figure 3C ). The FITC-myristoyl-CM4 signal on the cells was stronger than the FITC-CM4 signal after incubation for 30 minutes. The relative amounts of sialic acid on the surface of the three cell lines were determined by FITC-SNA, a specific lectin that binds to a-2,6 linked sialic acid. The a-2,6 linked sialic acid content in leukema cells (K562/MDR, and Jurkat cells) was significantly higher than that of HEK293 cells ( Figure 3D ). The relative amounts of PS on the surfaces of HEK-293, K562/MDR, and Jurkat cells were also determined by Annexin V-FITC, as a specific lectin that binds PS. The PS content of leukemia cells (K562/MDR and Jurkat) was significantly higher than that of HEK293 cells, as shown by flow cytometry ( Figure 3E ). These data suggested that myristoyl conjugation increased the membrane affinity of K562/MDR and Jurkat cells for myristoyl-CM4. Furthermore, the membrane affinities of myristoyl-CM4 to K562/MDR and Jurkat cells were markedly higher than its affinities to HEK293 cells and erythrocytes, while leukemic cells expressed more phosphatidylserine and sialylated glycoconjugate on the cell surface than normal cells. LDH is an intracellular enzyme that is released when the cell membrane is disrupted. Treatment with myristoyl-CM4 for different times resulted in LDH release ( Figure 4C ). LDH release from Jurkat cells was less than 10% at all tested concentrations (3, 9, 30 μM), while LDH release from K562/MDR cells was about 20% after treatment with 3 μM myristoyl-CM4 for 16 hours, and 30% at 30 μM. Virtually no LDH was released from either K562/MDR or Jurkat cells after CM4 treatment. These results suggested that myristoyl-CM4 could induce both apoptosis and necrosis in K562/MDR cells, but only apoptosis in Jurkat cells.
Myristoyl-CM4 induced necrosis and/or apoptosis in leukemia cells
Myristoyl-CM4 affected the mitochondria in leukemia cells
Cellular uptake of myristoyl-CM4 was examined using FITC-labeled peptides and rhodamine 123 as a specific probe for localizing mitochondria in living cells. Myristoyl-CM4 co-localized with mitochondria in K562/MDR and Jurkat cells ( Figure 5A ). After transport to the intracellular compartment, myristoyl-CM4 could be located on mitochondria. Disruption of mitochondrial integrity is one of the early events leading to apoptosis. We, therefore, examined changes in the mitochondrial membrane potential using the fluorescent dye, JC-1. JC-1 accumulated in intact mitochondria and formed aggregates with high Δψm, emitting red fluorescence. When the mitochondria collapse, the JC-1 fluorescence shifts from red to green. Greenfluorescence increased in K562/MDR and Jurkat cells after exposure to 2 μM and 3 μM myristoyl-CM4, respectively ( Figure 5B), and the green/red ratio increased from 0.02 to 0.17 in K562/MDR cells and from 0.02 to 0.40 in Jurkat cells. These data showed an obvious shift in JC-1 fluorescence from red to green, indicating disruption of the Δψm induced by myristoyl-CM4. ROS were quantified in K562/MDR and Jurkat cells using DCFH-DA fluorescent dyes ( Figure 5C ). DCFH fluorescence increased after treatment with myristoyl-CM4, both in K562/MDR and Jurkat cells, compared with PBS cintrol cells, indicating obvious ROS generation in K562/MDR and Jurkat cells induced by myristoyl-CM4.
Myristoyl-CM4 induced mitochondria-dependent apoptosis
Bcl-2/Bax family proteins play major roles in modulating mitochondria-dependent apoptosis. Therefore, the expression of pro-apoptotic Bax, and anti-apoptotic Bcl-2 were detected in myristoyl-CM4-treated K562/MDR and Jurkat cells by Western blot analysis ( Figure 6A ). Myristoyl-CM4 increased the expression of proapoptotic Bax and decreased the expression of antiapoptotic Bcl-2 in concentration-dependent manners in both K562/MDR and Jurkat cells ( Figures 6B and C) . The Bax/Bcl-2 ratio was significantly increased following myristoyl-CM4 treatment (P<0.001) ( Figure 6D ). These results implied that myristoyl-CM4 might induce apoptosis through a Bcl-2/Bax-mediated mitochondrial dysfunction pathway.
We further characterized the apoptotic pathway induced by myristoyl-CM4 by examining the activation of procaspase 9 (a caspase that initiates mitochondria-dependent apoptosis), and procaspase 3 (an important effector of mitochondria-mediated apoptosis pathway) by Western blot analysis. Myristoyl-CM4 significantly increased levels of active (cleaved) caspase 9, and active (cleaved) caspase 3. About 55% of procaspase 9 and 55% procaspase 3 were activated in K562/MDR cells after treatment with 2 μM myristoyl-CM4 ( Figures 6E and F) . The cleaved caspase 9/total caspase 9 and cleaved caspase 3/total caspase 9 ratios were both significantly increased in Jurkat cells after treatment with 3 μM or 6 μM myristoyl-CM4. More than 40% of PARP was finally cleaved by 3 μM myristoyl-CM4 in Jurkat cells or by 2 μM myristoyl-CM4 in K562/MDR cells ( Figure 6G ). These results indicated that myristoyl-CM4 could induce the mitochondria-dependent apoptotic signaling in both Jurkat and multi-drug resistant K562/MDR leukemia cells.
Discussion
In addition to their innate immune effect in pathogenic microbes, some AMPs can also target mammalian cells and may display selective activity towards tumor cells, making them attractive novel candidate anticancer agents. 22 AMPs such as LfcinB, cecropin A, PaDef defensin, and Arminin 1α-C have shown anticancer activity against various leukemia cells, with IC 50 values ranging from 10-60 μM. [9] [10] [11] [12] In the current study, CM4 showed very weak cytotoxicity against K562/MDR and Jurkat leukemia cells, but this cytotoxicity was increased by attaching a myristoyl to its N-terminus of CM4, with IC 50 values of 2 μM and 3 μM in K562/MDR and Jurkat cells, respectively. As the first binding target, the plasma membrane plays an important role in the anticancer activity of AMPs, and interactions with the plasma membrane, leading to its disruption or permeation, represent a major anticancer mechanism for most AMPs. The myristoyl group is hydrophobic, and we speculated that the enhanced cytotoxicity of myristoyl-CM4 compared with CM4 may result from enhanced interaction between the peptide and the plasma membrane. Indeed, the binding of myristoyl-CM4 was increased 14-fold and 19-fold in K562/MDR and Jurkat cells, respectively, compared with CM4. As a widelyrecognized form of protein fatty-acylation, myristoylation plays essential roles in directing the cellular localization of proteins by facilitating protein-membrane interactions. The myristoyl group may act as a lipid anchor in cell membranes for the N-myristoylated-protein, allowing peptides with high hydrophobicity to penetrate deeper into the hydrophobic core of the cell membrane. 17, 23 The current results were in accord with our previous study in breast cancer, which also found that myristoyl-CM4 showed enhanced binding to breast cancer cells. 21 21, 24 In the current study, we detected the sialic acid expression on the surface of leukemia cells, and found the sialic acid content in leukema cells (K562/MDR and Jurkat cells) was significantly higher than that of HEK293 cells. We also detected the phosphatidylserine content. Phosphatidylserine is a negatively charged phospholipid present in significant proportions in the inner monolayer of the plasma membrane of normal cells, Certain tumor cells show elevated levels of phosphatidylserine on the outer membrane leaflet, which may contribute to the selective cytotoxicity to cancer cells. [25] [26] [27] Interestingly, we found that the PS contents of the outer membrane leaflets of both K562/MDR and Jurkat cells were higher than in normal PBMCs and HEK293 cells. Thus, the higher contents of sialic acid and PS may explain the increased binding activity of myristoyl-CM4 to K562/MDR and Jurkat leukemia cells compared with healthy normal cells. All our current data supported the observed higher cytotoxicity of myristoyl-CM4 against leukemia compared with healthy cells. The hydrophibicity, amphibicity, and length of native CM4 prevented it from internalizing in leukemia cells, whereas myristoyl-CM4 could enter into cells, including leukemia and breast cancer cells. This implied that myristoyl was crucial for cellular entry, highlighting the importance of hydrophobic interactions. Regarding the role of myristoylation in membrane binding, in order to achieve stable membrane binding, N-myristoylated proteins employ a second signal, such as polybasic regions, hydrophobic residues, another membrane-bound binding partner, or a second lipid modification. 28, 29 CM4 is a cationic molecule (net charge +5) with an amphipathic α-helix at the N-terminus and hydrophobic α-helix at the C-terminus. 16 We speculated that the hydrophobic interaction of myristoyl-CM4 with the lipid bilayer membrane of leukemia cells may result from both the myristoyl group and the hydrophobic helix. Indeed, myristoyl-CM4 was shown to be more hydrophobic than CM4 by reverse phase-high-performance liquid chromatography (data not shown). Nelson et al 30 revealed conjugated to the 14-carbon myristate group was efficiently loaded into lymphocyte-derived cells. Furthermore, myristoylated virus proteins played an important role in membrane fusion and host entry. 31 Lipid modification was previously shown to enhance the passive transport of some drugs mediated by the lipid moiety, and increased antitumor efficacy could be achieved by increasing cell permeability and retention of anticancer agents using lipidconjugation strategies. 32 Myristoylation may, thus, be a useful tool for transporting AMPs into the interior of cancer cells. Necrosis and apoptosis are the two main anticancer mechanisms of most α-helical AMPs. 33 The present results
showed that, after internalization into leukemia cells, myristoyl-CM4 could target mitochondria and affect their function, including disrupting the Δψm, increasing ROS accumulation, and the Bax/Bcl-2 ratio, then activating of caspases 9 and 3, and cleaving PARP to induce apoptosis.
It has been suggested that leukemia is characterized by an impaired balance between the proliferation of blood cells and their capacity to undergo apoptosis, and the Bcl-2 family of anti-apoptotic (such as Bcl-2) and proapoptotic (such as Bax) proteins are critical regulators of apoptosis in leukemia. 34 Both Bax and Bcl-2, as well as Bax/Bcl-2 ratio, have been regarded as prognostic markers in various cancers, including leukemia. 35 We, therefore, examined the expression of Bax and Bcl-2 proteins. Bax levels were very low in Jurkat cells, and the Bax/Bcl-2 ratio was about 0.5. However, 6 μM myristoyl-CM4 increased the Bax level, and the Bax/Bcl-2 ratio increased to 2.5. Myristoyl-CM4 also increased the level of Bax and Bax/Bcl-2 ratio and decreased the level of Bcl-2 in K562/ MDR cells. As a central cell death regulator, Bax is an indispensable gateway to mitochondrial dysfunction and a major pro-apoptotic member of the Bcl-2 family proteins. 36 Increased levels of the Bax and an increased Bax/Bcl-2 ratio thus contributed to apoptosis of K562/ MDR and Jurkat cells. In contrast, myristoyl-CM4 decreased the levels of Bcl-2 in K562/MDR and Jurkat cells, with Jurkat cells being more sensitive than K562/ MDR cells. Among the Bcl-2 family, Bcl-2 is overexpressed in acute and chronic leukemias and seems to play an important role, not only in disease pathogenesis, but also in resistance to chemotherapy. 37, 38 Myristoyl-CM 4 may, thus, be an effective candidate agent for activating anti-apoptotic Bax proteins. Lower concentrations of AMPs have previously been reported to promote apoptosis of cancer cells, while higher concentrations primarily resulted in cancer cell death through membrane disruption. 39 Wang and Zhou 40 found that the AMPs temporin-1CEɑ could directly disrupt the plasma membrane and cause lysis of breast cancer cells at higher concentrations, but initiated cell death by an intracellular mechanism at lower concentrations. Interestingly, myristoyl-CM4 induced both mitochondria-mediated apoptosis and cell membrane disruption in K562/MDR cells at lower concentrations (3 μM), suggesting that it had a stronger interaction with the cell membrane in K562/ MDR cells compared with Jurkat cells. Myristoyl-CM4 also exerted an obvious direct membrane-disrupting effect at higher concentrations (30 μM). Chemotherapy serves an essential role in leukemia treatment; however, it is frequently accompanied by the development of multidrug resistance, resulting in treatment failure. Overexpression of P-gp results in the export of chemotherapeutic agents from cancer cells, thus preventing the intracellular accumulation of active drug such as doxorubicin. 41, 42 We showed that K562/MDR cells were resistant to doxorubicin, and confirmed that they expressed high levels of P-gp in the plasma membrane, which were significantly decreased by myristoyl-CM4. Moreover, myristoyl-CM4 showed strong cytotoxicity against K562/MDR leukemia cells via at least two mechanisms (necrosis and apoptosis). These results implied that myristoyl-CM4 may be a potential candidate for overcoming P-gp-mediated multidrug resistance, leading to better outcomes for leukemia chemotherapy.
Conclusion
In summary, the current study showed that myristoyl-CM4 had effective cytotoxicity against leukemia cell lines (K562/ MDR and Jurkat) and had less cytotoxicity to normal cells (HEK-293, L02 cells, mouse PMBCs, and erythrocytes). This anticancer activity may be attributable to the high affinity of myristoyl-CM4 to the leukemia cell membrane and its internalization within leukemia cells. The membrane affinities of myristoyl-CM4 to K562/MDR and Jurkat cells were markedly higher than its affinities to HEK293 and erythrocytes, and leukemic cells expressed more phosphatidylserine and sialylated glycoconjugate on the cell surface than normal cells, which could explain its selective cytotoxicity to cancer cells. Myristoyl-CM4 affected mitochondrial function to induce mitochondria-dependent apoptosis in both K562/MDR and Jurkat cells, but also induced necrosis in K562/MDR cells by direct membrane disruption. Myristoyl-CM4, thus, appears to be a promising candidate for an anti-leukemia agent, particularly in relation to multidrug-resistant leukemia.
Abbreviation list
MTT, 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide; Rho123, Rhodamine 123; DAPI, 4,6-diamidino-2-phenylindole; DMEM, Dulbecco's Modified Eagle's Medium; ROS, Reactive Oxygen Species; DCFH-DA, 2ʹ,7ʹ-dichlorofluorescin-diacetate; PI, propidium iodide; LDH, Lactate dehydrogenase; ROS, Reactive oxygen species; PBMCs, Peripheral blood mononuclear cells; PBS, Phosphate buffer saline; PS, phosphatidylserine; PARP, poly-ADP ribose polymerase; GAPDH, lyceraldehyde 3-phosphate dehydrogenase.
